Table 3

Histopathological features of patients diagnosed with endometrial cancer

VariableAllNon-SLN
(Group 1)
SLN
(Group 2)
P value
All cases21754 (24.9)163 (75.1)
Histotype0.193
 Endometrioid212 (97.7)54 (100)158 (96.9)
 Non-endometrioid5 (2.3)0 (0.0)5 (3.1)
Grading0.059
 1–2200 (92.2)53 (98.1)147 (90.2)
 317 (7.8)1 (1.9)16 (9.8)
LVSI0.119
 Negative-focal185 (85.3)50 (92.6)135 (82.8)
 Substantial32 (14.7)4 (7.4)28 (17.2)
Tumor diameter<0.001
 <20 mm292 (63.5)142 (74.0)150 (56.0)
 ≥20 mm168 (36.5)50 (26.0)118 (44.0)
Myometrial invasion0.692
 <50%175 (80.6)45 (83.3)130 (79.8)
 ≥50%42 (19.4)9 (16.7)33 (20.2)
Cervical invasion0.172
 No205 (94.5)53 (98.1)152 (93.3)
 Yes12 (5.5)1 (1.9)11 (6.7)
Immunohistochemical features
 p530.620
 WT105 (94.6)27 (96.4)78 (94.0)
 Mutated6 (5.4)1 (3.6)5 (6.0)
 NA1062680
MMR0.820
 Proficient93 (83.8)23 (85.2)70 (83.3)
 Deficient18 (16.2)4 (14.8)14 (16.7)
 NA1062779
ER0.516
 Negative4 (4.3)1 (7.7)3 (3.8)
 Positive89 (95.7)12 (92.3)77 (96.3)
 NA1244183
PR0.516
 Negative4 (4.3)1 (7.7)3 (3.8)
 Positive89 (95.7)12 (92.3)77 (96.3)
 NA1244183
Staging system and risk groups
FIGO stage0.224
 IA164 (75.6)43 (79.6)121 (74.2)
 IB28 (12.9)8 (14.8)20 (12.3)
 II10 (4.6)1 (1.9)9 (5.5)
 III A-B-C15 (6.9)2 (3.7)123 (8.0)
Prognostic risk groups*0.092
 Low155 (71.4)41 (75.9)114 (69.9)
 Intermediate21 (9.7)7 (13.0)14 (8.6)
 High to intermediate24 (11.1)4 (7.4)20 (12.3)
 High17 (7.8)2 (3.7)15 (9.2)
  • Values shown as n (%) unless stated otherwise.

  • *Classified according to the ESGO-ESTRO-ESP classification.13

  • ER, estrogen receptor; FIGO, International Federation of Gynecology and Obstetrics; LVSI, lymphovascular space invasion; MMR, mismatch repair; NA, not available; PR, progesterone receptor; SLN, sentinel lymph node; WT, wild type.